Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers (8/4/2008)
Researchers affiliated with the Cancer Programs, American College of Surgeons, recommend that at least 15 lymph nodes be removed and examined in patients with early gastric or pancreatic cancers. The results of this study were published in the July 2008 issue of the Archives of Surgery.

Normalization of N-telopeptide Associated with Improved Survival from Bone Metastasis Treated with Bisphosphonates (6/25/2008)
Researchers involved in a multicenter international trial have reported that normalization of N-telopeptide of type I collagen (NTX) levels is associated with skeletal-related events and survival among patients with bone metastases from solid tumors treated with Zometa® (zoledronic acid) or Aredia® (pamidronate). These results were published in the July 1, 2008 issue of Cancer.

Gemzar® Improves Survival in Early Pancreatic Cancer (6/9/2008)
Researchers from Germany have reported that adjuvant Gemzar® (gemcitabine) significantly improves disease-free and overall survival of patients with early pancreatic cancer. The details of this study were reported in a late-breaking abstract at the 2008 meeting of the American Society of Clinical Oncology May 30 to June 2 in Chicago.

Abraxane®/Gemzar® Promising in Pancreatic Cancer (4/24/2008)
Researchers from the Scottsdale Clinical Research Institute in Arizona have reported that Abraxane® (paclitaxel) and Gemzar® (gemcitabine) appeared promising for the treatment of advanced pancreatic cancer. These results were recently presented at the 2008 annual meeting of the American Association for Cancer Research, April 12-16, 2008 in San Diego.

Addition of Erbitux® Does Not Improve Outcomes in Pancreatic Cancer (4/14/2008)
Researchers from Italy have reported that the addition of Erbitux® (cetuximab) to Gemzar® (gemcitabine) and Platinol® (cisplatin) does not improve outcomes compared with chemotherapy only in advanced pancreatic cancer. These results were published in the January 2008 issue of Lancet Oncology.